Biocryst Pharma Inc (BCRX) Stock Price, Quote & News

Company Profile

BioCryst Pharmaceuticals, Inc., a biotechnology company, developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated and seasonal influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat HAE. It is also developing BCX17725, a protein therapeutic for netherton syndrome which is in...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 919 859 1302

Fax: 919 859 1314

Website: www.biocryst.com

Address:

4505 Emperor Boulevard, Suite 200, Durham, United States

JPtheBCRXdestroyer1 Apr. 4 at 7:12 PM

$BCRX pricing in the buyout at 8. Gotta close those 4 dollar gaps on the forthcoming bad phase 3 data.

1 · Reply

Thinkingman91 Apr. 4 at 2:38 PM

$BCRX did it touch $13 premarket? Hit 10’and you held didn’t you

3 · Reply

raylin Apr. 4 at 1:49 PM

$BCRX From Endpoints:

1 · Reply

Krisis289 Apr. 4 at 1:27 PM

$BCRX you got this bulls 💪🏻 buy out is on the horizon! "Trust me bro" is a reliable source! 🙌 Bears telling you to take profit at the top are dumb😵‍💫🤡🛝🧱😂😂 BIG week ahead

1 · Reply

Fergus20 Apr. 4 at 11:56 AM

$BCRX I am king Fergus

0 · Reply

Del_Gue Apr. 4 at 10:29 AM

$BCRX Buy, Hold, Get Rickets.

0 · Reply

Del_Gue Apr. 4 at 10:27 AM

$BCRX Never pull an offering.

2 · Reply

Del_Gue Apr. 4 at 10:27 AM

$BCRX Applesauce.

0 · Reply

Del_Gue Apr. 4 at 10:26 AM

$BCRX Drink a full glass of water with 9930.

0 · Reply

Del_Gue Apr. 4 at 10:25 AM

$BCRX Inducement grants the first of next month.

0 · Reply

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Feb 26, 2026, 7:00 AM EST - 5 weeks ago

BioCryst Reports Full Year 2025 Financial Results and Provides Business Update

Feb 17, 2026, 7:00 AM EST - 6 weeks ago

BioCryst to Present at Upcoming Investor Conference

Feb 11, 2026, 7:00 AM EST - 7 weeks ago

BioCryst to Present New HAE Data from ORLADEYO® (berotralstat) and Navenibart at the 2026 American Academy of Allergy, Asthma & Immunology Annual Meeting

Feb 5, 2026, 7:01 AM EST - 2 months ago

BioCryst to Report Fourth Quarter 2025 Financial Results on February 26

Jan 23, 2026, 9:00 AM EST - 2 months ago

BioCryst Completes Acquisition of Astria Therapeutics, Expanding Leadership in Hereditary Angioedema

Jan 12, 2026, 7:00 AM EST - 2 months ago

BioCryst Announces Preliminary Full Year 2025 ORLADEYO® (berotralstat) Net Revenue of $601 Million (+37 percent y-o-y), Beating Prior Guidance Range

Jan 6, 2026, 7:00 AM EST - 3 months ago

BioCryst to Present at 44th Annual J.P. Morgan Healthcare Conference

Dec 12, 2025, 7:06 AM EST - 4 months ago

FDA expands approval of BioCryst's rare disease drug for use in young children

Dec 12, 2025, 7:00 AM EST - 4 months ago

BioCryst Announces FDA Approval of ORLADEYO® (berotralstat) Oral Pellets, First and Only Oral Prophylactic Treatment for Patients with HAE Aged 2 to

Dec 3, 2025, 7:00 AM EST - 4 months ago

BioCryst Receives Early Termination of HSR Waiting Period for Astria Acquisition

Nov 6, 2025, 8:00 AM EST - 5 months ago

BioCryst Presents New Data at ACAAI Highlighting Burden of HAE on Pediatric Patients and Caregivers and Sustained Reduction of Attacks in Children Treated with One Year of ORLADEYO® (berotralstat)

Nov 3, 2025, 7:00 AM EST - 5 months ago

BioCryst Reports Third Quarter 2025 Financial Results and Provides Business Update

Oct 23, 2025, 7:00 AM EDT - 5 months ago

BioCryst to Present New Pediatric HAE Data at the American College of Allergy, Asthma & Immunology 2025 Annual Scientific Meeting

Oct 20, 2025, 7:00 AM EDT - 5 months ago

BioCryst to Report Third Quarter 2025 Financial Results on November 3

Oct 17, 2025, 3:20 PM EDT - 6 months ago

Astria Therapeutics Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Astria Therapeutics, Inc. - ATXS

ATXS

Oct 14, 2025, 12:20 PM EDT - 6 months ago

BioCryst Says Astria Therapeutics $700 Million Deal Gives 'Perfect Second Product Candidate'

ATXS

Oct 14, 2025, 7:35 AM EDT - 6 months ago

BioCryst to buy Astria Therapeutics in $700 million deal

ATXS

Oct 14, 2025, 7:00 AM EDT - 6 months ago

BioCryst to Acquire Astria Therapeutics, Strengthening Presence in HAE, Transforming Growth Profile

ATXS

Oct 1, 2025, 7:00 AM EDT - 6 months ago

BioCryst Completes Sale of European ORLADEYO® (berotralstat) Business

Aug 11, 2025, 7:00 AM EDT - 8 months ago

BioCryst Announces Departure of Dr. Helen Thackray

Aug 4, 2025, 7:00 AM EDT - 8 months ago

BioCryst Reports Second Quarter 2025 Financial Results and Provides Business Update

Jul 31, 2025, 7:00 AM EDT - 8 months ago

BioCryst Announces Charlie Gayer to Succeed Jon Stonehouse as Chief Executive Officer Upon his Retirement in December

Jul 21, 2025, 7:00 AM EDT - 9 months ago

BioCryst to Report Second Quarter 2025 Financial Results on August 4

Jul 9, 2025, 7:00 AM EDT - 9 months ago

BioCryst to Highlight Patient-focused Research at the 2025 US HAEA National Summit

Jul 7, 2025, 7:00 AM EDT - 9 months ago

BioCryst Appoints Babar Ghias Chief Financial Officer and Head of Corporate Development

Jun 27, 2025, 7:00 AM EDT - 10 months ago

BioCryst Announces Sale of European ORLADEYO® (berotralstat) Business to Neopharmed Gentili for up to $264 Million

Jun 16, 2025, 7:00 AM EDT - 10 months ago

BioCryst Presents New Data on the Long-term Efficacy and Safety of ORLADEYO® (berotralstat) Across all Ages at EAACI

Jun 13, 2025, 7:00 AM EDT - 10 months ago

ORLADEYO® (berotralstat) Approved in Colombia

Jun 6, 2025, 7:00 AM EDT - 10 months ago

BioCryst Achieves Reimbursement for ORLADEYO Across all Major European Countries

Jun 2, 2025, 7:00 AM EDT - 10 months ago

BioCryst to Present New Data at 2025 Meeting of the European Academy of Allergy and Clinical Immunology

May 30, 2025, 7:00 AM EDT - 11 months ago

BioCryst Highlights Real-world Data Showing ORLADEYO® (berotralstat) Consistently Reduces HAE Attacks Across All Ages

May 27, 2025, 7:00 AM EDT - 11 months ago

BioCryst to Present at Upcoming Investor Conferences

May 16, 2025, 7:00 AM EDT - 11 months ago

BioCryst Presents New Real-world Evidence Showing Significant and Sustained Reductions in HAE Attack Rates in Adolescents and People with Severe HAE Following Initiation of ORLADEYO® (berotralstat)

May 14, 2025, 7:00 AM EDT - 11 months ago

BioCryst Announces FDA Acceptance of NDA for ORLADEYO® (berotralstat) Oral Granules in Patients with Hereditary Angioedema Aged 2 to 11 Years

May 5, 2025, 5:29 PM EDT - 11 months ago

BioCryst Pharmaceuticals Soars 23% In One Session - Here's Why It Surprised Investors

May 5, 2025, 7:00 AM EDT - 11 months ago

BioCryst Reports First Quarter 2025 Financial Results and Provides Business Update

May 1, 2025, 7:00 AM EDT - 1 year ago

BioCryst Appoints Steve Frank to Board of Directors

Apr 21, 2025, 7:00 AM EDT - 1 year ago

BioCryst to Report First Quarter 2025 Financial Results on May 5

Feb 24, 2025, 11:49 AM EST - 1 year ago

BioCryst Pharmaceuticals Unveils Latest Trial Data, Reports Mixed Q4 Earnings

Feb 24, 2025, 7:00 AM EST - 1 year ago

BioCryst Reports Fourth Quarter and Full Year 2024 Financial Results and Upcoming Key Milestones

Feb 24, 2025, 6:00 AM EST - 1 year ago

BioCryst Announces Positive Results from APeX-P Trial for ORLADEYO® (berotralstat) in Pediatric Patients with Hereditary Angioedema Aged 2 to

Feb 12, 2025, 7:00 AM EST - 1 year ago

BioCryst Launches ORLADEYO® (berotralstat) in Portugal

Feb 10, 2025, 8:30 AM EST - 1 year ago

BioCryst to Present New ORLADEYO® (berotralstat) Results from APeX-P Pediatric Trial at 2025 American Academy of Allergy, Asthma & Immunology / World Allergy Organization Joint Congress

Feb 10, 2025, 7:00 AM EST - 1 year ago

BioCryst to Report Fourth Quarter 2024 Financial Results on February 24

Jan 10, 2025, 7:00 AM EST - 1 year ago

BioCryst Announces Preliminary Full Year 2024 ORLADEYO® (berotralstat) Net Revenue of $437 Million (+34 percent y-o-y)

Jan 7, 2025, 7:00 AM EST - 1 year ago

BioCryst to Present at 43rd Annual J.P. Morgan Healthcare Conference

Nov 18, 2024, 2:00 AM EST - 1 year ago

BioCryst Launches ORLADEYO® (berotralstat) in Ireland

Oct 21, 2024, 7:00 AM EDT - 1 year ago

BioCryst to Report Third Quarter 2024 Financial Results on November 4

JPtheBCRXdestroyer1 Apr. 4 at 7:12 PM

$BCRX pricing in the buyout at 8. Gotta close those 4 dollar gaps on the forthcoming bad phase 3 data.

1 · Reply

Thinkingman91 Apr. 4 at 2:38 PM

$BCRX did it touch $13 premarket? Hit 10’and you held didn’t you

3 · Reply

raylin Apr. 4 at 1:49 PM

$BCRX From Endpoints:

1 · Reply

Krisis289 Apr. 4 at 1:27 PM

1 · Reply

Fergus20 Apr. 4 at 11:56 AM

$BCRX I am king Fergus

0 · Reply

Del_Gue Apr. 4 at 10:29 AM

$BCRX Buy, Hold, Get Rickets.

0 · Reply

Del_Gue Apr. 4 at 10:27 AM

$BCRX Never pull an offering.

2 · Reply

Del_Gue Apr. 4 at 10:27 AM

$BCRX Applesauce.

0 · Reply

Del_Gue Apr. 4 at 10:26 AM

$BCRX Drink a full glass of water with 9930.

0 · Reply

Del_Gue Apr. 4 at 10:25 AM

$BCRX Inducement grants the first of next month.

0 · Reply

Del_Gue Apr. 4 at 10:25 AM

$BCRX Buyout on M&A Tuesday.

0 · Reply

Del_Gue Apr. 4 at 10:24 AM

$BCRX Biowar 2.0 on Monday.

0 · Reply

Del_Gue Apr. 4 at 10:24 AM

$BCRX

0 · Reply

Paulzk Apr. 4 at 9:52 AM

$BCRX Off to bed.

0 · Reply

Paulzk Apr. 4 at 9:48 AM

$BCRX Is Gold still a golden investment at current levels? “People don’t have, typically, an adequate amount of gold in their portfolio,” Dalio told CNBC in 2025 (10). “When bad times come, gold is a very effective diversifier.” JPMorgan Chase CEO Jamie Dimon has also struck a bullish tone, suggesting that in the current environment, gold could “easily” rise to $10,000 an ounce .

0 · Reply

Paulzk Apr. 4 at 9:44 AM

$BCRX Skilled Trades: Manufacturing and maintenance sectors face acute shortages of experienced technicians and managers.

0 · Reply

Paulzk Apr. 4 at 9:43 AM

$BCRX Urban Areas: In 85% of major metro areas where the U.S.-born population declined between 2018 and 2023, immigrant growth fully offset the loss.

0 · Reply

Paulzk Apr. 4 at 9:42 AM

$BCRX AI Overview The retirement of roughly 10,000 Baby Boomers daily is driving an unprecedented workforce contraction, expected to drop U.S. labor participation from 62% in 2023 to ~58% by 2030. This exodus creates massive talent gaps, talent shortages, and loss of institutional knowledge, specifically impacting healthcare, manufacturing, and construction Economic Impact: Immigration has become the sole driver of growth in the U.S. working-age population. The FWD.us analysis suggests that raising immigration by 50% would be necessary to fully meet future labor needs and counteract the "graying" of the American workforce

0 · Reply

Paulzk Apr. 4 at 9:40 AM

$BCRX The U.S. requires about 1.6 million immigrants annually to maintain the current size of its workforce, which is crucial for supporting an aging population. Current Dependence: Immigration accounted for 84% of U.S. population growth in 2023–24 and 71% in 2024-25, highlighting its role as the primary driver of growth. Zero Immigration Scenario: The population would shrink every year, falling to approximately 226 million by 2100 (a 32% decline from 2022 levels).

0 · Reply

Paulzk Apr. 4 at 9:35 AM

$BCRX Immigration is economically OK as long as you have jobs for the immigrants and they have the skills needed. Also it is important that they contribute more in taxes then they collect in benefits. To stabilize its population and workforce, the US needs a consistent net migration of roughly 1.5 million people annually. Without this level of immigration, the U.S. population is projected to start declining around 2033, driven by a declining birth rate, leaving immigration as the primary driver of national population growth

0 · Reply

Paulzk Apr. 4 at 9:26 AM

$BCRX Just a guess but if the replacement fertility rate is 2.1 and we are at 1.6 then we need immigration to stabilize the population. Migration Cliff: Net international migration is expected to fall to roughly 321,000 people by July 2026, down from 1.3 million the previous year. Aging Population: The median age in the U.S. is estimated to be 38.7 years in 2026. Urbanization: Approximately 83.1% of the population (290 million people) is expected to live in urban areas. CBO's projections, the U.S. population grows from 349 million people in 2026 to 364 million in 2056, and the average age rises. Starting in 2030, annual deaths exceed annual births, and net immigration accounts for all population growth.

1 · Reply

Paulzk Apr. 4 at 9:15 AM

$BCRX Cost remain high Still, costs remain high. Since January 2020, the price of groceries has risen about 30%, the cost of electricity has surged 41% and the cost of car insurance is up by 56%, according to Bloomberg

0 · Reply

Market Cap	2.26B
Revenue (ttm)	874.84M
Net Income (ttm)	263.86M
EPS (ttm)	N/A
PE Ratio	7.05
Forward PE	34.74
Profit Margin	30.16%
Debt to Equity Ratio	-4.02

Volume	7,824,900
Avg Vol	5,586,530
Day's Range	N/A - N/A
Shares Out	250.80M
Stochastic %K	10%
Beta	0.70
Analysts	Strong Sell
Price Target	$20.18